Ethier Isabelle, Johnson David W, Bello Aminu K, Ye Feng, Osman Mohamed A, Levin Adeera, Harris David C H, Kerr Peter, Liew Adrian, Wong Muh Geot, Lunney Meaghan, Saad Syed, Zaidi Deenaz, Khan Maryam, Jha Vivekanand, Tonelli Marcello, Okpechi Ikechi G, Viecelli Andrea K
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Division of Nephrology, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
Kidney Int Suppl (2011). 2021 May;11(2):e86-e96. doi: 10.1016/j.kisu.2021.01.004. Epub 2021 Apr 12.
Oceania and South East Asia (OSEA) is a socioeconomically, culturally, and ethnically diverse region facing a rising epidemic of noncommunicable diseases, including chronic kidney disease (CKD). The second iteration of the International Society of Nephrology Global Kidney Health Atlas aimed to provide a comprehensive evaluation of kidney care in OSEA. Of the 30 countries/territories in OSEA, 15 participated in the survey, representing 98.5% of the region's population. The median prevalence of treated kidney failure in OSEA was 1352 per million population (interquartile range, 966-1673 per million population), higher than the global median of 787 per million population. Although the general availability, access, and quality of kidney replacement therapy (i.e., dialysis and transplantation) was high in OSEA, inequalities in accessibility and affordability of kidney replacement therapy across the region resulted in variability between countries. According to the survey results, in a third of the participating countries (mostly lower-income countries), less than half the patients with kidney failure were able to access dialysis, whereas it was readily available to all with minimal out-of-pocket costs in high-income countries; similar variability in access to transplantation was also recorded. Limitations in workforce and resources vary across the region and were disproportionately worse in lower-income countries. There was little advocacy for kidney disease, moderate use of registries, restricted CKD detection programs, and limited availability of routine CKD testing in some high-risk groups across the region. International collaborations, as seen in OSEA, are important initiatives to help close the gaps in CKD care provision across the region and should continue receiving support from the global nephrology community.
大洋洲和东南亚(OSEA)是一个社会经济、文化和种族多元化的地区,面临着包括慢性肾脏病(CKD)在内的非传染性疾病流行加剧的问题。国际肾脏病学会全球肾脏健康地图集的第二次迭代旨在对大洋洲和东南亚地区的肾脏护理进行全面评估。在大洋洲和东南亚的30个国家/地区中,有15个参与了调查,占该地区人口的98.5%。大洋洲和东南亚地区接受治疗的肾衰竭患病率中位数为每百万人口1352例(四分位间距为每百万人口966 - 1673例),高于全球每百万人口787例的中位数。尽管大洋洲和东南亚地区肾脏替代治疗(即透析和移植)的总体可及性、可获得性和质量较高,但该地区肾脏替代治疗在可及性和可负担性方面的不平等导致了国家之间的差异。根据调查结果,在三分之一的参与国家(主要是低收入国家),不到一半的肾衰竭患者能够获得透析治疗,而在高收入国家,所有人都能轻松获得透析治疗,且自付费用极低;移植的可及性也存在类似差异。劳动力和资源的限制在该地区各不相同,在低收入国家情况尤其糟糕。该地区对肾脏疾病的宣传很少,登记处的使用适度,慢性肾脏病检测项目受限,一些高危人群中常规慢性肾脏病检测的可及性有限。正如在大洋洲和东南亚地区所看到的,国际合作是帮助缩小该地区慢性肾脏病护理差距的重要举措,应继续得到全球肾脏病学界的支持。